The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Synthetic immunity to cancer has been pioneered by the application of chimeric antigen
receptor (CAR) engineering into autologous T cells. CAR T cell therapy is highly amenable …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

Simple Summary Unlike B cell malignancies, the progress on generating an adoptive T cell
therapy for relapsed/refractory acute myeloid leukemia (AML) remains insufficient. This …

Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic
efficacy in the clinic and can even mediate curative responses in patients with hematologic …

Acute Myeloid Leukemia (AML) is an aggressive myeloid malignancy associated with high
mortality rates (less than 30% 5-year survival). Despite advances in our understanding of the …

Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia
(T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of …

Simple Summary Chimeric antigen receptor (CAR)-T cell therapy has been highly
successful in treating hematological malignancies like leukemia and lymphoma, leading to …

Measurable residual disease (MRD), defined as the population of cancer cells that persist
following therapy, serves as the critical reservoir for disease relapse in acute myeloid …

Backgrounds Chimeric antigen receptor (CAR)-T cell therapy has achieved unprecedented
success in treating hematopoietic malignancies. However, this cell therapy is hampered in …